Heart failure & cardiomyopathies
Effect of Dapagliflozin on 6-Minute Walk Distance in Heart Failure With Preserved Ejection Fraction: PRESERVED-HF
Primary result · Improvement in 6MWT distance ≥15 mResult — go to the resultAdjusted odds ratio 1.66 95% CI 1.00–2.75Authors' conclusion
Compared with those on placebo, patients with heart failure with preserved ejection fraction randomized to dapagliflozin were more likely to experience a clinically meaningful improvement and less likely to experience a deterioration in physical function over 12 weeks as measured by 6MWT distance.
Study context
- Population
- Patients with HFpEF6MWT at baseline and 12 weeks
- Participants
- 289 patients
- Comparison
- Dapagliflozin vs placebo
- Primary endpoint
- Clinically meaningful improvement in 6MWT distance ≥15 m
- Follow-up
- 12 weeks
Methodological detailsdouble-blind, responder analysis
- Double-blind
- Responder analysis
Primary result
Improvement in 6MWT distance ≥15 m
Adjusted odds ratio
1.66
95% CI 1.00–2.75
P = 0.05
Events by treatment group
Dapagliflozinvs Placebo
adjusted OR 1.66 (95% CI 1.00–2.75); P = 0.05
As reported in the abstract
Further findings
| Outcome | Adjusted OR (95% CI) | P value | |
|---|---|---|---|
| Reduction in 6MWT distance ≥15 m · 12 weeks | 0.56 (0.33–0.94) | P = 0.03 | |
| 0.20.5125Adjusted odds ratio (log scale) |
Prespecified subgroups
- Results consistent across all prespecified subgroups
- All interaction P values not significant
Original publication
Effect of Dapagliflozin on 6-Minute Walk Distance in Heart Failure With Preserved Ejection Fraction: PRESERVED-HF. Circ Heart Fail. Published 23 October 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →